Objective: Major depressive disorder is the most common psychiatric disorder, worldwide,
yet response and remission rates are still unsatisfactory. The identification of genetic …

Genome-wide association studies (GWAS) of antidepressant treatment outcome have been
at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match …

Major depressive disorder (MDD) is an emergent cause of personal and socio‐economic
burden, both for the high prevalence of the disorder and the unsatisfying response rate of …

Introduction: Depression is responsible for the most part of the personal and socio-economic
burden due to psychiatric disorders. Since antidepressant response clusters in families …

The pharmacogenetics of antidepressants has been not only a challenging but also
frustrating research field since its birth in the 1990s. Indeed, great expectations followed the …

Background It has been suggested that outcomes of antidepressant treatment for major
depressive disorder could be significantly improved if treatment choice is informed by …

Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and
up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD …

Background Major depressive disorder (MDD) has a high personal and socio-economic
burden and> 60% of patients fail to achieve remission with the first antidepressant. The …

Background: Antidepressant medication is a major cornerstone in treatment of mood and
anxiety disorders. Numerous substances are available on the market; however, only 60% of …

Personalized medicine—the adaptation of therapies based on an individual's genetic and
molecular profile—is one of the most promising aspects of modern medicine. The …